Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 16/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12542958 | 0.86 | TEK (0.43) | IMPDH2MYCIMPDH1MKNK1MKNK2 | |
| SCHEMBL3208642 | 0.79 | IMPDH2 (0.64) | IMPDH2AAK1IMPDH1MKNK1MKNK2 | |
| SCHEMBL4881547 | 0.79 | CTNNB1 (0.48) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL12542745 | 0.79 | IMPDH2 (0.42) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL12542845 | 0.78 | IMPDH2 (0.56) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL12542749 | 0.70 | IMPDH2 (0.52) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL4879222 | 0.69 | CTNNB1 (0.42) | IMPDH2AAK1 | |
| SCHEMBL15741721 | 0.69 | PARP1 (0.49) | IMPDH2 | |
| SCHEMBL1906120 | 0.68 | IMPDH2 (0.62) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL1010203 | 0.68 | MYC (0.62) | IMPDH2MYCAAK1IMPDH1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | TIE1, FLT4, CDK1 | IMPDH2 2796/4885MYC 626/4885AAK1 517/4885 |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | TIE1, AURKB, TEK | IMPDH2 3365/4885MYC 637/4885AAK1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.